ARS Pharmaceuticals, Inc. — Director's Dealing 2026

Jan 5, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2026-01-02

Reporting Person: Karas Eric (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-02	Stock option (right to buy)	$11.49	A	240000	Acquired	2036-01-01	Common Stock (240000)	Direct

Footnotes

F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.